Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus TACE/TAE versus TACE/TAE alone for intermediate-stage hepatocellular carcinoma
ISRCTN12053408Phase 2Active, not recruiting
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of nivolumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Primary endpoints: 3-month TACE/TAE progression and Overall survival. Started Nov 2020; status: active, not recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ISRCTN12053408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12053408.